首页> 美国卫生研究院文献>Maney MORE Open Choice >Fluid management for dengue in children
【2h】

Fluid management for dengue in children

机译:儿童登革热的液体管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dengue is a serious public health problem worldwide. Dengue shock syndrome (DSS), the severe form of dengue fever, can cause death within 12–24 hours if appropriate treatment is not promptly administered. For patients with DSS and the 30% of non-shocked dengue patients who require intravenous fluid therapy, a range of solutions is available for plasma volume support. Crystalloid solutions, such as normal 0·9% saline or Ringer’s lactate, are the ones most commonly used. In severe cases, colloid solutions may be administered for their greater osmotic effect, although they carry a greater risk of adverse events. This paper summarises the key clinical data, comparing fluid regimens in children with severe dengue, and concludes that the majority of patients with DSS can be treated successfully with isotonic crystalloid solutions. If a colloid is thought necessary, a medium-molecular-weight preparation that combines good initial plasma volume support with good intravascular persistence and an acceptable side-effect profile is optimal. Further research should aim to determine whether there are benefits to early treatment with colloids, and which colloid solution is most effective for resuscitation of DSS patients.
机译:登革热是全世界严重的公共卫生问题。如果不及时采取适当的治疗措施,登革热的严重形式-登革热休克综合征(DSS)可能在12-24小时内导致死亡。对于有DSS的患者以及需要静脉输液治疗的30%非休克型登革热患者,有一系列解决方案可用于血浆容量支持。最常用的是晶体溶液,例如0.9%的生理盐水或林格氏乳酸盐。在严重的情况下,尽管胶体溶液具有更大的不良反应风险,但仍可因其更大的渗透作用而给药。本文总结了关键的临床数据,比较了严重登革热儿童的输液方案,并得出结论,大多数等渗性DSS患者可以使用等渗晶体溶液成功治疗。如果认为胶体是必需的,则最佳的中分子量制剂是将良好的初始血浆容量支持与良好的血管内持久性以及可接受的副作用相结合的中分子量制剂。进一步的研究应旨在确定胶体的早期治疗是否有益,以及哪种胶体溶液对DSS患者的复苏最有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号